Search results for "Menorrhagia"

showing 6 items of 6 documents

Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses

2013

In women of fertile age, iron loss consequent to excessive menstrual discharge is by far the most frequent cause of iron-deficient anemia. However, the relationship between menstrual discharge and iron loss is poorly understood. In this prospective study, total menstrual and iron losses were assayed in a large cohort of non-anemic women and women with excessive menstrual blood losses (menorrhagia) in order to provide data useful for intervention. One hundred and five Caucasian women aged 20–45 years were recruited. Blood cell count and serum ferritin (SF) levels were determined in each case before menses. Menstrual fluid losses (MFL) were determined using a standardized pads’ weight method.…

Adultmedicine.medical_specialtyAnemiaIronIron deficient anemiaPhysiologyIron deficiency Excessive mesntrual blood lossesYoung AdultIron lossesInternal medicineHumansMedicineErythropoiesisProspective StudiesYoung adultProspective cohort studyMenorrhagiaMenstrual bloodGynecologyHematologyAnemia Iron-Deficiencybusiness.industryIron deficiencyIron deficiency; Iron deficient anemia; Iron losses; Menstrual blood lossesHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseMenstrual blood lossesMenstruationCohortErythropoiesisFemalebusinessAnnals of Hematology
researchProduct

Ulipristal acetate versus leuprolide acetate for uterine fibroids

2012

A b s t r ac t Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of −20%. Results Uterine bleed…

Adultmedicine.medical_specialtyUterine fibroidsIntention to Treat AnalysiUrologyAdministration OralEndometriumInjections Intramuscularlaw.inventionchemistry.chemical_compoundYoung AdultEndometriumPrimary outcomeRandomized controlled trialDouble-Blind MethodlawUlipristal acetateSelective progesterone receptor modulatormedicineUterine NeoplasmUlipristalMenorrhagiaGynecologyIntention-to-treat analysisLeiomyomabusiness.industryObstetrics and GynecologyUterine bleedingUterine fibroids uterine leiomyomas uterine bleeding ulipristal acetate leuprolide acetate medical therapyGeneral MedicineNorpregnadieneMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E Ostetriciamedicine.anatomical_structurechemistryAmenorrheaFemalemedicine.symptomLeuprolidebusinessHuman
researchProduct

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies

2016

Introduction A paucity of data exists on the incidence, diagnosis and treatment of bleeding in women with inherited factor VII (FVII) deficiency. Aim Here we report results of a comprehensive analysis from two international registries of patients with inherited FVII deficiency, depicting the clinical picture of this disorder in women and describing any gender-related differences. Methods A comprehensive analysis of two fully compatible, international registries of patients with inherited FVII deficiency (International Registry of Factor VII deficiency, IRF7; Seven Treatment Evaluation Registry, STER) was performed. Results In our cohort (N = 449; 215 male, 234 female), the higher prevalence…

MalePediatricsFactor VII Deficiency030204 cardiovascular system & hematologyCohort Studieschemistry.chemical_compound0302 clinical medicineAntifibrinolytic agentgynaecological bleedingRegistriesChildGenetics (clinical)Aged 80 and overFactor VIIIncidence (epidemiology)Hazard ratio[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineFactor VIIMiddle AgedAntifibrinolytic AgentsRecombinant Proteins3. Good healthPhenotypeTreatment OutcomeChild PreschoolCohortFemalewomengynaecological bleeding; inherited factor VII deficiency; recombinant activated factor VII; womenCohort studyAdultmedicine.medical_specialtyAdolescentMucocutaneous zoneHemorrhageFactor VIIaYoung Adult03 medical and health sciencesmedicineHumansMenorrhagiaAgedProportional Hazards ModelsCoagulantsbusiness.industryProportional hazards modelInfantrecombinant activated factor VIISurgeryROC Curvechemistryinherited factor VII deficiencybusiness030215 immunology
researchProduct

(A)symptomatic necrotizing arteritis of the female genital tract.

2000

Abstract Aims: The vasculitides represent a heterogenous set of disorders that differ in prognosis and response to therapy. Beside systemic vasculitides, the development of localized forms of arteritis is well known though uncommon and the etiopathogenesis is not yet definitely clear. Methods: Patients with necrotizing arteritis of the female genital tract proven by histology are studied in a retrospective analysis. Results: Three cases of necrotizing arteritis with histological features of panarteritis nodosa apparently confined to the female genital tract are presented. None of these patients had prior history of systemic vasculitis. The acute necrotizing vasculitis was confined only to t…

Pathologymedicine.medical_specialtyCervix UteriNecrotizing VasculitismedicineHumansSex organArteritisMenorrhagiaFallopian TubesAgedRetrospective StudiesPolyarteritis nodosabusiness.industryVascular diseaseOvaryObstetrics and GynecologyGenitalia FemaleMiddle Agedmedicine.diseasePrognosisPolyarteritis NodosaReproductive MedicineMyometriumHistopathologyFemaleUterine HemorrhageVasculitisbusinessSystemic vasculitisEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery

1999

Objective: To obtain information on the efficacy of repeated short cycles of GNRH agonist treatment in order to avoid hysterectomy in near-menopausal women with symptomatic fibroids. Study design: 72 pre-menopausal women (mean age 50 years) with one or more uterine fibroids >10 cm in diameter, symptomatic menorrhagia lasting three months or more and haemoglobin=9 g/dl entered the study. The patients were randomized with ratio of approximately 1:4 to: (a) immediate surgery; or (b) treatment with goserelin acetate. Patients randomized to goserelin acetate received a first cycle of 3.6 mg depot once every 28 days for four months. They were followed-up for three years. If menorrhagia was observ…

medicine.medical_specialtyFibroidsRandomizationUterine fibroidsmedicine.medical_treatmentOvariectomyHysterectomylaw.inventionGonadotropin-Releasing HormoneRandomized controlled triallawmedicineHumansFibroids; Hysterectomy; Medical treatmentMenorrhagiaGynecologyHysterectomyLeiomyomabusiness.industryGoserelinGoserelin AcetateObstetrics and GynecologyMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryMenopauseLeiomyomaReproductive MedicinePremenopauseGoserelinFemalebusinessMedical treatmentmedicine.drugHuman
researchProduct